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ABSTRACT 
JIAN JIANG: Immuno Tandem Mass Spectrometry (iMALDI) Assay for Clinical 
Diagnostics 
(Under the direction of Christoph H. Borchers) 
 
For infectious diseases and cancers, currently there is no ideal diagnostic 
method.  I present here an iMALDI assay that holds the promise as the future 
platform of clinical diagnostics. It uses immobilized anti-peptide antibodies and 
MALDI-MS to detect and quantify protein expression and modification levels.   By 
determining peptide MW with MS and sequence with MS/MS, the iMALDI assay is 
highly sensitive and nearly absolutely specific.  Furthermore, this technology is safe 
and capable of absolute quantitation, multipexing and high-throughput analysis. The 
iMALDI-based diagnostics has been developed for Francisella tularensis (F. 
tularensis), an infectious bacterium, and the epidermal growth factor receptor 
(EGFR), a marker for several cancers. 
F. tularensis has been designated as one of the ten organisms most likely to 
be engineered for bioterrorism.  Methods for early and specific diagnosis are of 
critical importance.  The F. tularensis iMALDI assay provides unambiguous detection 
of F. tularensis peptides at attomole levels from peptide solutions, and at low CFU 
levels from bacteria. It allows absolute quantitation of the F. tularensis target peptide 
and therefore the parent protein.  It is able to provide absolute specificity, avoiding 
“false positives” from the non-specific binding.  The assay is also 
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applied to samples that are more useful for screening large populations, such as 
nasal swabs and urine. It is also safe. 
EGFR is highly expressed in a variety of tumors, and is therefore an important 
biomarker for cancer diagnosis and a target for cancer therapy.  The EGFR iMALDI 
assay can detect EGFR in the low attomole range in buffer and in one mammalian 
breast cancer cells.  It is highly specific.  It also allows absolute quantitation of the 
target peptide and therefore the parent protein.   This technique is capable of 
detecting EGFR in tumors.  
The iMALDI assay can be easily adapted to other target peptides and 
therefore has broad applications in clinical diagnosis and therapy selection of other 
pathogens and diseases. 
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CHAPTER  
1 OVERVIEW 
 
1.1 Infectious diseases 
In the USA, each year the number of cases of illnesses recognized related to 
significantly greater.  Infectious diseases result in substantial morbidity and mortality 
(2).  To win the battle over infectious diseases requires critical and timely 
intervention that relies on rapid and accurate detection of the pathogen in the acute-
care setting and beyond.  
attention toward the threat of bioterrorism has been considerably increasing.  For 
front-line acute care physicians to initiate appropriate response measures, rapid 
recognition and accurate diagnosis of real or suspected bioterrorism events is critical 
(3). 
1.2 Cancers 
In industrialized countries, cancer is one of the leading causes of death.  
Each year the number of diagnosed new cases of cancer worldwide is about 10 
million.  Despite recent substantial progress made in cancer therapy due to 
advances in molecular medicine, genomics, proteomics, and translational research, 
infectious diseases is over 5 million (1).  The number of cases unrecognized is 
Since the anthrax outbreak after the September 11, 2001 terrorist attacks, 
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our current efforts to combat cancer are not very successful.  Mortality rates for the 
most prevalent cancers have not been significantly reduced.  Some of the best 
available options to decrease overall mortality from cancer include primary 
prevention and earlier diagnosis (4).  If the disease can be detected early enough, 
there may be an opportunity to drastically reduce the burden of cancer.  The earlier 
a cancer is detected, the better the chances of treating it successfully.  For example, 
the earliest diagnosis of breast cancer could bring 5-year survival rates up to 98% 
(5).  
 
1.3 Clinical diagnosis 
1.3.1 Time  
Not only in cases of infectious diseases where acute care is usually needed, 
and cancers of which mortality is high, but also in any other cases of diseases, early 
diagnostics is necessary.   The earlier a disease is detected, the better the chances 
of treating it successfully, and the earlier the patients and their families’ suffering 
ends.  Otherwise, some diseases may develop to a more severe condition.  The 
patients would need more care and some may have to stay in hospital.  It leaves the 
patients and their families more suffering and greater economic burden. This also 
adds more burdens on health care workers and the hospitals, health insurance 
companies and the whole health care system in terms of workload and expenses.   
In the worst cases, some diseases that are curable in the beginning or not lethal 
themselves, just because it was discovered too late, can develop so serious as to 
become incurable or convert to some other untreatable lethal diseases and even 
cause death.  These are unnecessary at all and should be avoided with best effort.  
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However, a person usually cannot tell whether he or she is sick or need go to 
hospital at the very beginning of a disease’s development.  When we go to see a 
doctor, the disease probably has already progressed to a certain stage.  Since the 
populace has limited medical knowledge that is apparently not enough for self-
diagnosis, this delay is unavoidable.  The majority cases of cancer are diagnosed 
only after tumors have metastasized, which leaves the patient with a grim prognosis 
and delays treatment.  Thus, a rapid reliable diagnostic assay, which allows for 
accurate identification of pathogens and informed early therapeutic intervention 
would be invaluable (3).   
 
1.3.2 Costs 
As mentioned previously, no matter to the patients or the health care system, 
slow and delayed diagnosis is expensive in terms of time and effort.  The later the 
treatment is delayed, the more it costs.  A diagnostic tool itself should not be too 
costly to limit its accessibility to the populace either.  Otherwise, its application in 
clinics would be very limited.   
 
1.3.3 Sensitivity 
A diagnosis should be sensitive and avoid false negatives.  False negatives 
can cause some consequences as same as slow and delayed diagnosis.  Because 
the disease is not detected, treatment is delayed, and the best timing for treatment 
may have been missed.  Some diseases can progress to severe stage, or even 
cause death that can be avoided if detected and treated in time. Patients and their 
families suffer more and longer, with greater economic burdens.   
 4 
 
 
 
1.3.4 Specificity 
When referring to a medical test, clinical specificity refers to the percentage of 
people who test negative for a specific disease among a group of people who do not 
have the disease.   Here, “specificity” means that there are no “false positives” – i.e., 
the test result is specific for the target organism/disease. 
A diagnostic method, if gives too many false positive results, even if it is rapid, 
cost-effective and sensitive, it is still not a useful clinical tool.  Speed and relatively 
low cost do not mean poor quality.  When a diagnostic method is being evaluated, 
specificity is another important factor.   
For people who do not have the disease, a “false positive” result causes them 
unnecessary pains and troubles.  All efforts to treat an illness that actually does not 
exist would be wasting our already limited resources.  For people who have another 
disease different from the diagnosed one, it results in a wrong treatment, which can 
pose great dangers to the patients.  
 
1.3.5 Quatitation 
Some diseases, such as cancers, are detected by the detection and 
quantitaion of some biomarkers that are characteristic of certain types of cancer.  
The staging of the diseases may also be based on the level of the biomarkers.  Not 
only in clinical but also in research laboratories, quantitation of some specific target 
reagents, such as proteins, peptides and organisms, can provide a lot of useful 
information.  Therefore, quantitation capability of a diagnostic method is also 
important and useful.   
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1.3.6 High throughput analysis 
The capability of a diagnostic method for high throughput analysis is 
important for screening large populations. 
 
1.3.7 Safety 
An ideal diagnostic method should be safe.  Some methods, such as 
traditional culture-based methods, because they have to keep the organisms alive, 
pose hazards not only to the laboratory personnel, but also potentially to the 
populace if the disease-inducing reagents leak out of the laboratories by any chance.  
Although strict laboratory practice measures can be taken, no absolute safety can be 
guaranteed.  
 
1.4 Current techniques 
1.4.1 Overview 
For infectious diseases and cancers, there are enormous diagnostic methods.  
Each has its pros and cons.  For example, although culture-bases techniques are 
most widely used in conventional hospital laboratories, these techniques are slow, 
insensitive, unspecific and hazardous.  Immunohistochemistry (IHC) is a sensitive 
method for cancer diagnosis, but due to its poor staining and high noise level, its 
specificity is low.  Molecular diagnostics have been herald as “the diagnostics of the 
new millionaire”.  Because they detect and analyze on molecular levels, they have a 
lot of incomparable advantages that conventional methods lack, such as the 
molecular specificity.  They can be specific to DNA or protein level to different extent.  
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The enzyme-linked immuno sorbent assay (ELISA) and polymerase chain reaction 
(PCR) are both sensitive and widely used, while PCR is more rapid.  Some 
diagnostics, such as ELISA and PCR, have more or less quantitation capabilities, 
some very limited though. 
Some current diagnosis techniques are reviewed in the following sections, in 
two categories, cell and molecular based respectively.  Some of them are already 
widely used in clinics for years, some are also widely used in research laboratories, 
and some are still under development but have potential for future clinical 
applications. 
 
1.4.2 Cell-based diagnostics 
1.4.2.1 Culturing 
In a traditional culturing method, the organism is cultured in a medium 
containing some kind of chemical reagent that will indicate the physical property 
change of the medium because of the organism growth.   
Culturing is widely used in conventional hospital laboratories. However, 
culturing is cumbersome, requiring intensive labors and additional special settings.  
It is time consuming.  Assays for fastidious pathogens can be extremely prolonged, 
up to several weeks.  Its low sensitivity can result in high false negatives.  
Characterization of detected pathogens, e.g. discernment of species, strain, 
virulence factors, requires additional testing and more time.  For patients who have 
received antibiotics, test sensitivity is diminished.  Sometimes they are unable to 
culture certain pathogens in disease states associated with microbial infection.  
 7 
 
 
Because the organisms must be kept alive, it is also hazardous to laboratory 
personnel.  
Limitations of conventional culturing methods make such tests unreliable and 
inadequate for clinical diagnosis of infectious diseases, not to mention timely and 
accurate detection of bioterrorism agents in suspected outbreaks.  
 
1.4.3 Molecular-based diagnostics 
Molecular diagnostics, heralded as the “diagnostic tool for the new 
millennium”, is revolutionizing the clinical practices, especially in acute care settings 
where timely and accurate diagnostic tools are critical for patient treatment decisions 
and outcomes (3). 
Molecular methods diagnose on molecular level through the detection, 
characterization and/or quantification of signature molecules, such as nucleic acids 
and proteins. Unlike in conventional culture-based tests, the presence of viable 
organisms is not required for the identification of infectious agents, such as bacteria, 
viruses, and fungi, and therefore the detection of difficult to culture microorganisms 
is possible (6). 
Although the costs of molecular testing may be relatively high compared to 
most traditional clinical laboratory tests, the average cost per test may actually not, 
and the overall cost to the health system may be ultimately decreased due to 
improved diagnosis efficiency.  
Molecular-based diagnostics can be categorized into two groups, DNA/RNA-
based and protein-based. 
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1.4.3.1 DNA/RNA-based diagnostics 
1.4.3.1.1 Fluorescent in situ hybridization (FISH) 
Fluorescent in situ hybridization, or FISH, a cytogenetic technique which 
studies the structure of chromosome material, has emerged as a powerful clinical 
and research tool. Compared to routine cytology, it is relatively simple, very robust, 
more sensitive, and thus applicable in material of lesser quality (7). 
In FISH, a fluorescent probe binds to those parts of the chromosome with 
which it shows a high degree of sequence similarity. Then fluorescence microscopy 
is used to find out where the fluorescent probe binds to the chromosome.  
FISH is used to detect and localize specific DNA sequences on chromosomes. 
It can identify different chromosomal abnormalities including changes in 
chromosome number, translocations, deletions, rearrangements, and duplications.  
 
1.4.3.1.2 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) is a technique for enzymatically replicating 
DNA. 
The PCR reaction takes place in a thermocycler. Each PCR cycle consists of 
three major steps. (1) “Denaturation”: heated to a certain temperature, double-
stranded template DNA is separated into single-stranded DNA. (2) “Annealing”: 
temperature lowered, the primers attach to their complementary target single DNA 
strands. (3) “Elongation”: the DNA polymerase extends the annealed primer along 
the DNA strand to generate new copy of the target DNA. At the end of each cycle, 
the newly synthesized DNA strands act as new targets for the next cycle. 
Subsequently, the cycle repeated multiple times, the target DNA is amplified 
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logarithmically. The PCR product is then identified by its size using agarose gel 
electrophoresis.  
PCR can be performed quantitatively, using fluorescent dyes and probes to 
measure the amount of amplified product in real time, which is known as real-time 
PCR (RT-PCR). It can quantify starting amounts of DNA, cDNA or RNA indirectly. It 
is oftern used to determine whether a sequence is present or not.  
Compared to conventional culture-based techniques,  PCR is more sensitive, 
specific, and rapid; it has been utilized for identifying organisms that are difficult to 
grow in vitro by existing culture techniques (3).  With all required reagents ready and 
reaction conditions optimized, a PCR reaction usually takes only a few hours. The 
detection of the reaction results does not take long either.   
Clinically, PCR has been used for detection of specific or broad-spectrum 
pathogen, evaluation of emerging novel infections, surveillance, early detection of 
bioterrorism agents, and antimicrobial resistance profiling.  In medical and biological 
research labs, PCR is commonly used for a variety of tasks, such as detection of 
hereditary diseases, identification of genetic fingerprints, diagnosis of infectious 
diseases, cloning of genes, paternity testing, and DNA computing.  
The greatest problem that hampered the widespread use of PCR in clinical 
settings comes from false-positive results. The predominant reason is the 
background DNA contamination from the products of earlier PCR reactions. These 
“carry-over” products may be transmitted through PCR reagents, tubes, pipettes, 
and laboratory surfaces. Even very minor amounts of carry-over contamination may 
be amplified, which lead to false-positive results.  Although contamination risks can 
be reduced by meticulous control measures, such as good laboratory practices and 
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physical separation of pre-amplification and post-amplification areas, these 
measures are not foolproof. PCR materials can be decontaminated by destroying 
DNA using, for example, ultraviolet irradiation, chemical treatment, and enzymatic 
digestion (8, 9).  However, these methods at the same time will diminish the assay 
sensitivity (3). 
Also, PCR assays may give false-negative results due to its failure. There 
may be problems associated with PCR processing. For instance, the primers may 
not work, the temperatures are possibly not optimized, and the annealing can fail.  
Because the sample volume that PCR assay accommodates is very small, when the 
concentration of infectious organisms in the sample is too low, the assay may not be 
sensitive enough and would yield false-negative results. Efforts to improve an 
assay’s detection sensitivity may need to be individually adjusted based on the 
assay’s clinical application and the microbial pathogen of interest.  
Detected pathogens need to be further characterized so that pathogens’ 
species or strains, virulence factors, and antimicrobial susceptibilities can be 
ascertained. Genetic sequences contain rich sources of information that can be 
analyzed for this purpose.  To acquire these sources of information, several target 
genes need to be amplified simultaneously in a single reaction, which is called 
multiplexing.  Multiplexing-PCR can be performed with different primer pairs used in 
a single reaction, but in this case annealing temperatures for each primer pair must 
be optimized to work correctly within a single reaction.  Oftentimes one or more of 
the target sequences do not amplify. Unless a single primer set can be found 
suitable for amplification of all these fragments, performing multiplex-PCR is very 
difficult.  In any multiplex-PCR, amplicon sizes should be separated by enough 
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difference in final base pair length to form distinct bands via gel electrophoresis. 
Although the real-time PCR with potential use of differentially labeled fluorescent 
probes to identify multiple amplified products simultaneously in a single assay holds 
promise (10).  Unfortunately, current ability to spectrally differentiate multiple 
fluorescent signals is quite limited (3).   
Typically, PCR products are detected and analyzed by gel-electrophoresis 
and sequencing techniques.  These approaches are laborious, time consuming, and 
not suitable for clinical applicability. The best way to analyze the resultant PCR 
products remains unclear. 
 
1.4.3.2 Protein-based diagnostics 
1.4.3.2.1 Agglutination 
Agglutination test is a blood test used to identify unknown antigens; a known 
antibody is added to blood with the unknown antigen, and whether or not 
agglutination occurs helps to indicate whether or not the antigen exists in the blood. 
It can be used for diagnosis of infection and to identify pathogens and blood types. 
Agglutination tests can be used to quantitate the level of antibodies in a 
sample.  Serial dilutions of the sample are made and then a fixed number of red 
blood cells or bacteria or other such particulate antigen are added. The maximum 
dilution that gives visible agglutination, called the “titer”, is determined. The results 
are reported as the reciprocal of the maximal dilution that gives visible agglutination. 
It is only semi-quantitative. 
The agglutination pattern is usually determined by visual examination, which 
is time consuming, cumbersome, and highly subjective. 
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1.4.3.2.2 Immunohistochemistry (IHC) 
Immunohistochemistry or IHC is widely used in the diagnosis of cancer 
through detection of specific molecular markers that are characteristic of particular 
cancer types. In common instances, biopsies are processed into sections with a 
microtome and the sections are incubated with an appropriate antibody.  The 
antibody is tagged to a visible lable of which the most popular is an enzyme that can 
catalyse a colour-producing reaction or a fluorophore. The site of antibody binding is 
then visualized under an ordinary or fluorescent microscope to localize the antigen in 
cells of a tissue section. 
IHC is also widely used in basic research to understand the distribution and 
localization of biomarkers in different parts of a tissue. It can also be used to 
visualise the interactions between multiple proteins. 
In IHC techniques, there are many potential problems affecting the outcome 
of the procedure. The two major problems are a poor signal/noise ratio and poor 
staining. To solve these problems requires time-consuming optimization steps. 
 
1.4.3.2.3 Enzyme-linked immuno sorbent assay (ELISA) 
The enzyme-linked immuno sorbent assay, or ELISA, is an immunology 
technique used to detect the presence of an antibody or an antigen in a sample. It is 
currently one of the most common applications of protein microarrays (11). 
Usually the ELISA test is performed in a 96-well microtiter plate.  In a typical 
“sandwich” ELISA  to detect a sample antigen, the well of the plate is coated with a 
capture antibody which serves to bind and concentrate the antigen onto the surface. 
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The sample is added for incubation and any antigen present binds to the capture 
antibody.  A detection antibody is added and binds to the same antigen as the 
capture antibody, but does so at a different site.  Then enzyme-linked secondary 
antibody is added and binds to detecting antibody. A substrate is added later and 
converted by the enzyme to a detectable form which causes a chromogenic or 
fluorogenic signal, indicating a positive reaction.  
The ELISA can be used for detecting the presence of an antigen or antibody 
in a qualitative format, or for determining its concentration in a quantitative format. A 
qualitative ELISA simplely provide a positive or negative reading between which the 
cutoff is determined by the analyst and may be statistical. In a quantitative ELISA, 
the target standard is diluted in series, and spot intensities are measured via 
imagery of the treated arrays and plotted against the protein concentrations. By 
fitting an appropriate function to the set of (intensity, concentration) measurement 
pairs, a standard curve is estimated (12).  The concentration of the sample is then 
estimated by fitting the spot intensity into the standard curve. 
There are several factors that determine the sensitivity and precision of an 
ELISA. These include but are not limited to: the affinity of antibodies; the amount of 
immobilized antigens or antibodies on a solid phase; the incubation time; the 
eddiciency of enzyme conjugates; methods for signal detection; and signal 
amplification.  Manipulating any of these or other factors could potentially enhance 
the detection signal and thereby improve the detection sensitivity of an assay.  The 
use of the matched pair of high-affinity reagents for a single analyte also helps to 
improve both the assay sentitivity and specificity. However, not compromising the 
ability of a system to determine the true value of the analyte requires extreme care 
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(13).  Moreover, ELISAs can only be applied to proteins for which paired antibodies 
and an antigen standard are available for the assay, which limits the applications of 
ELISAs (11). 
 
1.4.3.2.4 Surface-enhanced laser desorption/ionization-mass spectrometry (SELDI-
MS) 
Surface-enhanced laser desorption/ionization-mass spectrometry, or SELDI-
MS is an array based mass spectrometric method that can identify reproducible 
patterns of protein profiles.  It has been applied as a serum/plasma biomarker 
discovery platform that can be used for diagnosis, prognosis and monitoring of 
disease progression (14). 
SELDI-MS couples protein separation directly to presentation to the mass 
spectrometer. Proteins of interest are selectively absorbed onto a chemically 
modified surface and then subjected to mass spectrometric analysis.  Based on 
targets’ biochemical properties the surface can be modified in various ways in order 
to achieve varying affinity to different subsets of proteins for better protein separation.  
The surface can be modified for anion exchange, cation exchange, normal phase, 
reversed phase, and immobilized metal affinity chromatography (IMAC). The 
resulting mass spectra are analyzed by statistical tools to yield protein profiles (15). 
This method could work quantitatively if the surfaces used for molecule 
immobilization are specific for certain proteins (e.g. antibodies or other binders), or 
they have enough capacity to bind all the proteins applied to the sample (4). 
 
1.4.4 Summary 
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Each method has its own strengthes and weaknesses.  No single method will 
be optimal in all applications.  Our immuno tandem mass spectrometry (iMALDI) 
technique is developed to address some of the problems associated with these 
current methods such as culturing, PCR, SELDI and ELISA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
2 IMMUNO TANDEM MASS SPECTROMETRY (iMALDI) ASSAY 
 
2.1 Immuno tandem mass spectrometry (iMALDI) assay 
Immuno tandem mass spectrometry (iMALDI) assay is based on 
immunopurification of a representative peptide followed by identification and 
quantification of this peptide using MS.  It is the future platform of clinical diagnostics, 
which can be applied to quantify specific diagnostically relevant proteins.  This assay 
is inexpensive, highly sensitive, highly specific, quantitative and potential for high 
throughput analysis and safe. 
 
2.1.1 Scheme 
Basically, anti-peptide antibodies are produced and immobilized on affinity 
beads. The proteome of interest is proteolytically digested. Isotopically labeled 
epitope-containing peptides, called “heavy” peptides, are added into the digest as 
the internal standard for quantitation, and then incubated with the antibody-beads to 
immuno-adsorb the epitope-containing target peptides.  After immuno-adsorption, 
antibody-beads are arranged in a microarray/spot format on the MALDI-target plate. 
MALDI matrix solution is then added, which enables the elution of the affinity-bound 
peptides from the immobilized antibodies permitting MALDI-analysis of the peptides.  
The relative abundances of the molecular ion signals corresponding to the original or 
light and heavy peptides are used to quantify the amount of this protein in the
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original sample.  Absolute specificity can be achieved by mass spectrometric 
sequencing of the epitope containing peptide, using MALDI-MS/MS (Figure 1). 
 
2.1.2 Peptide vs. protein 
The iMALDI is based on detection and quantitation of peptides instead of 
proteins. Because peptides are more stable and less susceptible to denaturation, 
preserving native structure is not necessary and there’s no protein class restriction. 
The detected peptides can be sequenced for identification. 
 
2.1.3 Bead vs. plate 
For affinity capture, anti-peptide antibodies are immobilized on inexpensive 
affinity beads rather than on the surface of a plate as is done in the conventional 
protein chip technology, using standard immobilization techniques, therefore no 
specific protein surface chemistry required.  Moreover, compared to limited plate 
surface on chips, since the surface area of beads is larger, the binding capacity is 
increased, and therefore using beads surfaces could be more sensitive (16).  A 
planar array sometimes suffers from non-uniformity and slow diffusion of targets to 
the binding surface.  Using beads can circumvent these problems since the 
reactions proceed in a solution-like environment with solution kinetics. Moreover, the 
reactions proceed with an active mixing, which helps diffusion and therefore binding 
of the targets to the immobilized antibodies.  This can result in a gain of sensitivity 
and improve accuracy and reproducibility (17). The beads with different antibodies 
conjugated to the surface can be mixed together for multiplexing in which different 
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targets can be detected and analyzed simultaneously in one reaction. Therefore 
iMALDI assay has the potential for high throughput analysis.    
 
2.1.4 Highly specific capture reagents 
Because iMALDI is based on immunoaffinity capture, highly specific 
antibodies remain a prerequisite.  However, the current techniques for generation of 
antibodies can not guarantee generated antibodies are always highly specific.  In 
cases highly specific antibodies cannot be obtained, antibody mimics, such as 
aptermers, are alternative candidates. 
 
2.1.5 Costs 
A clinical diagnosis should be affordable and accessible to the populace. So 
its cost is one of the important factors that are critical to its development. For iMALDI, 
the costs of antibodies and MS instruments seem to be the major expenses.  
Generation and production of antibodies need to be cost-effective. It currently 
costs about $2,000~$2,500 to raise an antibody by a commercial company such as 
SIGMA-GENYSIS.  A package in this price range includes synthesis of the epitope-
containing peptide, ELISA analysis of the serum containing the developed antibodies, 
affinity purification, and host animal maintaining.  Although the price is not cheap, 
the amount of produced antibody is usually enough for analyzing quite an amount of 
samples.  The antibody cost per sample is actually not as high as it appears. 
Moreover, the technology is still developing.  In the future the antibody production 
will be more cost-effective. 
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Compared to other types of chemical analysis instruments, mass 
spectrometers are expensive.   But to use iMALDI, one does not have to have a 
mass spectrometer themselves.  They can send the samples to a facility that has the 
appropriate mass spectrometer for analysis.  Therefore the cost of MS instrument is 
actually not a big concern for iMALDI users. 
 
2.2 Mass spectrometry as the detection and analysis method 
MS analysis of peptides is rapid (a few seconds per sample by MALDI-MS), 
accurate, sensitive, and specific (because of the accurate determination of the 
molecular weight by MS and the accurate determination of the amino acid sequence 
by MS/MS).  These features allow the analyst to distinguish non-specifically-bound, 
and even cross-affinity-bound, peptides from the specific target epitope peptide.  
Mass spectrometry is also well suited for peptide/protein quantitation.  MS can 
perform relative quantitation using reference peptides from two different samples 
that have been differentially-labeled with stable isotopes, or absolute quantitation if a 
known amount of a stable-isotope labeled peptide has been added as an internal 
standard.   
 
2.2.1 Matrix-Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) 
MALDI-TOF MS is an important and popular analytic tool for identifying the 
mass identity of biomolecules. Typically, samples are mixed with an organic 
compound that acts as a matrix (protonated at acidic pH) to facilitate desorption and 
ionization of compounds in the sample. The analyte ions are then accelerated by an 
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applied high voltage (15-25 KV), separated in a field-free flight tube and detected as 
an electrical signal at the end of the flight tube.  
 
2.2.1.1 Matrix-Assisted Laser Desorption/Ionization (MALDI) 
Several advantages have been demonstrated with MALDI, including spectral 
simplicity due to singly charged ions, a high mass range (up to >900 kDa), low noise 
levels, high sensitivity, little sample consumption, short measurement times, average 
salt tolerance and minimal fragmentation.  
 
2.2.1.2 Time-of-flight (TOF) 
A Time-of-flight (TOF) mass analyzer separates ions and measures their m/z 
based on the time they spend to “fly” from the ion source to the detector.  A TOF 
mass spectrometry can be operated in the linear mode or the reflectron mode.  The 
latter is utilized for our analysis of peptides. Compared to the linear mode of TOF, 
the reflectron mode considerably improves mass resolution and thus mass 
accuracies.  
In the linear mode, due to the spatial distribution of ions in the ion source and 
their proximity to the applied electric field, not all the ions receive the same initial 
kinetic energy.  These factors give rise to relatively poor mass resolutions of the 
order of 100-500. This leads to components in mixtures being unresolved from one 
another and large errors (~1%) in molecular weight measurements.  
A reflectron is constructed of a stack of donut-shaped lens across which a 
high voltage is applied.  The potential applied across the lenses of the reflectron 
causes the ions that enter it to be gradually repelled. Ions of different kinetic 
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energies penetrate the mirror to differing degrees. These ions are then reflected 
down the same or second flight tube to a second detector. The difference in the flight 
path and time corrects for the differences in the kinetic energies of the ions so that 
they reach the detector at the same time. Furthermore the reflectron effectively 
extends the flight tube to almost twice its length, which can be seen to have a 
dramatic effect on an ion’s flight time. So the reflectron mode considerably improves 
mass resolution and thus mass accuracies. 
 
2.2.2 Tandem MS (MS/MS) 
The advantage of MS as readout platform for immunodetection is the high 
molecular specificity. The specificity is achieved by mass spectrometric sequencing 
of the epitope containing peptides, using Tandem MS (MS/MS). 
In Tandem MS or MS/MS, the peptide with a specific mass is selected, called 
the “precursor ion” or “parent ion”. The precursor ion is fragmented and the fragment 
ions are separated and detected.  Therefore an MS/MS spectrum can provide the 
sequence information of the precursor peptide ion.   A peptide can be fragmented in 
several ways, before, at or after the peptide bond, giving rise to “a” and “x” ions, “b” 
and “y” ions, “c” and “z” ions respectively. Usually the “b” and “y” ions that are 
produced from breaking the peptide bond are annotated. 
 
2.3 Applications 
The iMALDI has a wide range of applications, including but not limited to 
quantification of known clinical markers (peptides, proteins, carbohydrates, small 
molecules) with molecular specificity, quantification of biological warfare agents, and 
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identification of protein isoforms, variants, modifications. It can be applied in clinical 
environment and in army hospital type acute care settings. 
 
2.4 iMALDI vs. ELISA 
Like ELISAs, iMALDI is also an antibody-based technique.  Instead of binding 
to a surface, however, anti-peptide antibodies (not anti-protein antibodies) are bound 
to CNBr-activated sepharose, and the blocking of unreacted sites is also done on 
the beads.  Unlike ELISAs, however, analyte detection in iMALDI is not based on 
secondary colorimetry or fluorescence, but on the fundamental properties of the 
bound analyte – its molecular weight and amino acid sequence.   The iMALDI 
technique is sometimes referred to as a “peptide chip” assay because multiple 
samples can be analyzed by mass spectrometry as an array of different anti-peptide 
antibody beads on a MALDI target.  
Like ELISA, iMALDI does not require extensive protein separation, and low-
abundance proteins can be analyzed in the presence of high-abundance proteins, 
providing both speed and dynamic range.  Because peptides are more stable and 
less susceptible to denaturation, iMALDI should be more reproducible from sample 
to sample than ELISAs or chip techniques based on anti-protein antibodies, and 
sample storage requirement should not be as rigorous.   Unlike ELISAs, iMALDI 
requires only one anti-peptide antibody, which lowers the cost of antibody production.  
Antibodies are immobilized on inexpensive sepharose beads for affinity capture, as 
in the conventional affinity capture/elution/MALDI technique (18), rather than on the 
surface of a plate, thus eliminating the need for special surface chemistry.  
Additional advantages of using affinity beads are less-stringent sample storage 
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requirements after antibody immobilization, fewer complications resulting from 
denaturation of the capture antibody in solution, and the ability to incubate several 
types of beads with small volumes of tryptic-digested biological fluid instead of 
“soaking” the entire target.   
 
2.5 Summary 
In summary, the iMALDI uses only one antibody, so compared to ELISA that 
uses at least two antibodies, iMALDI is less expensive in terms of antibody 
production. In iMALDI, serial dilutions of the sample are not required. By using 
internal standards, iMALDI can be used for absolute quantitations. MS provides 
molecular specificity and protein isoforms specificity. The iMALDI is also an 
extremely flexible format.  Multiple antibodies can be used for multiplexing. The 
iMALDI has a wide range of applications. It is the future platform of clinical 
diagnostics. 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
3 iMALDI FOR DETECTION OF FRANCISELLA TULARENSIS 
 
3.1 Francisella tularensis (F. tularensis) 
Francisella tularensis (F. tularensis) is a small, nonmotile, aerobic Gram-
negative cocco-bacillus that causes tularemia.  The bacteria can penetrate unbroken 
skin, can survive and multiply within macrophages, and can then spread to various 
organs through the blood (19). Ten bacteria injected subcutaneously (20), 10-50 on 
contact with unbroken skin (21), 10-50 given by aerosol (22, 23), or 102 to108 
bacteria by ingestion (21) are sufficient to cause infection.  Humans who have direct 
physical contact with infected animals or insects, or have inhaled aerosolized 
bacteria, have a good chance of becoming infected.   Untreated, the mortality rate 
can be 30% (24). Although normally tularemia in humans is relatively rare, F. 
tularensis has the potential to be engineered for bioterrorism. 
Initial symptoms are flu-like and non-specific. They usually appear 3 days 
after exposure (25).  General laboratory tests (CRP, LDH, alkaline phosphatase, 
leukocytes, etc) are insufficient for diagnosis.  Because early antibiotic therapy (with 
streptomycin or gentamicin) can greatly reduce the lethality rate (26), an immediate 
diagnosis of an infection with F. tularensis is critical.  Because of the virulence of F. 
tularensis, the severity of the disease, the rapidity of progression from initial onset to 
seriousness or death, and the high mortality rate, several agencies (27) have been 
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concerned about the weaponization of F. tularensis, especially the use of 
aerosolized bacteria by terrorists as an airborne pathogen (28-30).  F. tularensis has 
been designated as one of the ten organisms most likely to be engineered for 
bioterrorism (31), and one of the six “category A bioterrorism organisms” (19, 29, 32-
34). 
 
3.2 Current diagnostic techniques for F. tularensis 
Bacteriological methods can be used for detecting F. tularensis (35), but 
culturing the organism is difficult (20, 22, 28, 36), time-consuming (sometimes taking 
several days), and is potentially hazardous to laboratory personnel (37).  Moreover, 
several studies have shown (38) that the sensitivities and specificities of these 
methods are low (note:  “specificity” means that there are no “false positives” – i.e., 
the test gives a positive result ONLY for the target organism). 
Since culturing F. tularensis is difficult, serological tests such as the bacterial 
microagglutination (MA) test, have been used to diagnose tularemia, but this takes 1 
week for measurable levels of antibodies to develop, and an additional week for 
sufficient antibody levels for a reliable test (28, 39-42).  Antibodies against 
Francisella may cross react with other organisms such as Brucella, Proteus OX19, 
and Yersinia spp. (28), which reduces the specificity and could lead to false positives.  
More recently, another type of serological test, an enzyme-linked immunosorbent 
assay (ELISA), achieved a detection limit of 103 bacteria/mL in PBS and 104 
bacteria/mL in human serum (43).  However, when samples are contaminated with 
other microorganisms (44), accurate diagnosis with ELISA or culturing methods is 
very difficult due to their low specificities.  
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PCR is a molecular method for detection of F. tularensis that usually only 
takes several hours per reaction.  A hand-held assay (HHA) PCR (43) could detect F. 
tularensis in 3 hours, and achieved the analytical sensitivity of 100 bacteria/mL PBS 
or 103 – 104 bacteria/mL serum (45).  A real-time Taq-Man PCR assay, combining 
multiple individual assays, showed a detection limit of one organism (46).  However, 
PCR may give false positives from contamination with other DNA, which lowers its 
specificity.  Moreover, simultaneous assaying for multiple species or virulence 
factors by PCR is difficult (3).  
 
3.3 iMALDI for F. tularensis 
The peptide-based immuno tandem mass spectrometry (iMALDI) assay 
circumvents many of the problems associated with PCR and ELISA, and is 
distinguished by its ability to provide absolute specificity, absolute quantitation, and 
high sensitivity.    
 The iMALDI assay for detection of F. tularensis is based on capture of the F. 
tularensis IglC aa 49-61 peptide.  This assay is capable of fast, safe, sensitive, and 
specific detection of F. tularensis in environmental samples. It can be used for 
absolute quantitation of target peptides and, therefore, for absolute quantitation of 
their parent proteins.   It is also demonstrated that iMALDI is applicable to the 
detection of F. tularensis in clinical samples, such as human plasma and nasal 
swabs.  
 
3.4 Materials and Methods 
3.4.1 Target protein 
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The 23kDa protein, IglC,  from F. tularensis bacteria is encoded by iglC, 
whose sequence has no significant homology to any other gene present in the 
GenBank database (47).  Live Vaccine Strain (LVS) bacteria, at a concentration of 
2.25x109 CFU (Colony Forming Units)/mL in 70% ethanol, were used.  The total 
protein concentration of the bacteria sample was 700ng/mL as determined with an 
ELX800 Universal Microplate Reader.  
 
3.4.2 Nasal swab samples  
Mice were inoculated intranasally with 1 x 105 CFU LVS.  Two, five and seven 
days post inoculation, a small, moist, alginate swab was used to rub across the 
nostrils of the mice.  The swab was then swirled in a tube containing 100 μL 
PBS.  Next, 100 μL of 95% ethanol was added to the sample to ensure inactivation.   
 
3.4.3 Tryptic digestion   
Digestion of human plasma (UNC blood bank) was carried out in 25mM 
ammonium bicarbonate (Sigma) at 37oC overnight.  A ~1:10 enzyme:substrate ratio 
of trypsin (Sequencing-grade modified trypsin, Promega) to protein was used.  The 
digested human plasma was spiked with F. tularensis peptides or a bacterial digest 
to mimic clinical samples.  Before digestion, the nasal swab solution was diluted with 
ammonium bicarbonate until the final concentration of ethanol was 38%, which is 
compatible with tryptic digestion.  
 
3.4.4 Antibody production and immobilization of antibodies on beads 
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This MALDI-MS-based technique to detect bacterial proteins from F. 
tularensis uses a customized antibody that was raised against an F. tularensis IglC 
peptide, selected because of its high sensitivity in MALDI-MS (Figure 2). 
Four F. tularensis IglC tryptic peptides, which are absolutely unique to, and 
thus diagnostic of F. tularensis, were selected for their high sensitivity in the MALDI-
MS mode (Figure 2).  These four peptides were synthesized by Sigma-Genosys.  
(Note:  a cysteine residue was added to some peptide sequences because of ready 
conjugation with carrier proteins).  Antibodies were raised against each peptide, and 
tested by ELISA to determine the detection sensitivities/efficiencies. The peptide that 
showed the highest binding efficiency was selected for use in the Francisella peptide 
chip, and the corresponding antibody was purified by Sigma-Genosys. 
 The anti-peptide antibody  was then immobilized on CNBr-activated 
sepharose (Amersham Pharmacia) according to the manufacturer’s instructions (48). 
Briefly, the CNBr beads react with the primary amine groups on the antibody, 
thereby covalently linking the antibody to the beads.  Excess binding sites on the 
beads are blocked by incubation with an amine-containing buffer, (in this case, Tris), 
and the process is completed by a series of washes at alternating pH. 
 
3.4.5 Immuno-adsorption protocol 
An aliquot of settled antibody-bead slurry (1-5 μL) was added to a compact 
reaction column (USB) and washed 4-5 times with 400 μL of 0.1x PBS. To mimic an 
environmental sample, a bacterial digest or synthetic F. tularensis IglC peptide 
(CNIVAIEGGEDVTK, aa 49-61) was dissolved in water/buffer and diluted to a series 
of concentrations, e.g. 25 ng/μL, 5 ng/μL, 0.5 ng/μL, etc.  A 20 μL aliquot of each 
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solution was incubated separately with a small amount  (1~5 μL) of antibody-beads 
to immuno-adsorb the epitope-containing peptide.  PBS was incubated with the 
antibody beads or unconjugated agarose beads as negative controls. F. tularensis 
bacteria spiked into a plasma digest mixture were used to mimic clinical samples. 
PBS was incubated with the antibody beads or unconjugated agarose beads as a 
negative control.  Three negative control experiments were performed by incubating 
(a) unconjugated agarose beads with PBS; (b) unconjugated agarose beads with 
synthetic peptide or bacteria digest sample; and (c) antibody-beads with PBS, 
respectively. 
 After incubation for 2-4 h at room temperature with end-to-end rotation on a 
“Labquake” rotator (Lab Industries), the beads were washed 6 times with 400 μL of 
freshly-made 50 mM ammonium bicarbonate, or 3 times with 400mM of NaCl 
(Sigma) followed by 3 times with 50 mM ammonium bicarbonate in case high levels 
of non-specific binding was expected in complex samples such as plasma.  The 
beads were re-suspended in a small volume of 50 mM ammonium bicarbonate (1-5 
μL) and an aliquot of the beads (0.5 μL) was spotted directly onto the MALDI target 
as described in the Results and Discussion section. 
 
3.4.6 Isotopic labeling for absolute quantitation   
The F. tularensis IglC aa 49-61 peptide 49NIVAIEGGEDVTK61 containing an 
isotopically-labeled valine at position 59 (underlined) (the "heavy" peptide) was 
synthesized at the UNC Peptide Synthesis Facility, using a 13C-labeled fmoc Valine 
purchased from Isotec/Sigma-Aldrich.  The increase in mass from the unlabeled 
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("light") F. tularensis IglC aa 49-61 peptide was 6 Da.  The synthesis was performed 
according the fmoc approach described in details elsewhere (49).  
 
3.4.7 Absolute quantitation 
The “heavy” peptide, dissolved in water (HPLC grade, Pierce) was used as an 
internal standard.  Heavy peptide was spiked into a F. tularensis bacterial digest in 
various amounts, immuno-adsorbd on anti-F. tularensis IglC peptide antibody beads, 
and quantitated by MALDI-MS analysis of the beads on the MALDI target. 
 
3.4.8 Mass spectrometric analysis 
MALDI-MS experiments were performed on Bruker Daltonics’ (Billerica, MA) 
Reflex III and Ultraflex MALDI-TOFs, using Bruker’s Anchor-chip MALDI-target 
plates (400 or 600 μm/384 spot format).  MS/MS analyses were carried out on an 
Applied Biosystems Voyager 4700 (Framingham, MA) MALDI-TOF/TOF.  The matrix 
used for all experiments was α-cyano-4-hydroxycinnamic acid (HCCA) (Sigma) after 
re-crystallization from hot methanol.  A saturated solution of HCCA in 50:49.9:0.1 
acetonitrile (Caledon Laboratories):water (HPLC grade, Pierce):trifluoroacetic acid 
(Pierce) was used.  Ammonium bicarbonate (ABC) solution (50mM) was added for 
easy placement of the beads on the MALDI target.  Following placement of the 
antibody beads on the target, 0.3-0.5 μL of HCCA matrix was added, and the spot 
was allowed to dry at room temperature. 
 
3.5 Results and Discussion 
3.5.1 Sensitivity 
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3.5.1.1 Detection of F. tularensis/bacteria in PBS solution 
By direct MALDI-MS analysis of the beads, the detection limit for the synthetic 
F. tularensis IglC peptide (cysteine was added for antibody production) was 
determined to be in the low attomole range (14 attomoles) in buffer (HPLC-grade 
water or PBS).  Without enrichment by iMALDI, in MALDI-MS analysis, the detection 
sensitivity of the peptide in buffer was in the low femtomole range (17 femtomoles) 
(Figure 3).  In the enrichment process, the peptides are bound to antibody beads, 
which greatly reduces losses due to adsorption by tubes and tips.  Moreover, when 
spotted on the target plate, even after elution by the matrix solution, the peptides do 
not spread out all over the spot area. Instead, they tend to aggregate at “hot spots”, 
and when the laser is focused at these “hot spots”, greatly increased detection 
sensitivities can be obtained. 
 
 The F. tularensis iMALDI assay, based on the anti-F. tularensis IglC, aa49-61 
antibody, can also detect the target F. tularensis peptide from a bacterial digest.  
The target F. tularensis peptide was determined in a bacterial digest equivalent to 80 
bacteria.  The bacteria were digested and incubated with a small aliquot (1-5 μL) of 
anti-aa 49-61 NIVAIEGGEDVTK antibody beads.  One tenth of the antibody beads 
were spotted on the MALDI target plate and analyzed directly.  Although there were 
signals from some unknown impurities or non-specifically bound peptides from, for 
example, the bacterial digest, the target peptide was still detectable by its mass.  
The singly-charged, epitope-containing tryptic peptide (aa 49-61 NIVAIEGGEDVTK) 
from the IglC protein was observed at m/z = 1344.7 (Figure 4).  Therefore the 
detection limit for bacteria in PBS solution is determined to be 8 CFU bacteria on 
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target by using 50% of the antibody beads incubated with 50μL of a bacterial 
solution in PBS, at a concentration of 320 CFU mL-1, which is as low as the most 
sensitive detection systems yet developed (46, 50).  It should be noted that 8 CFU 
does not represent the lowest possible detection limit in real applications, but is an 
estimate of the lowest possible detection limit of our method, as the tryptic digestion 
of the protein equivalent of 8 CFU might be difficult. 
 
3.5.1.2 Detection of F. tularensis bacteria in blood 
The following detection limits were determined for the synthetic F. tularensis 
IglC, aa49-61 and F. tularensis bacteria spiked into blood samples (plasma):  69 
attomoles of the F. tularensis IglC aa49-61 peptide and 800 CFU of bacteria (Figure 
5) on target by using 50% of the antibody beads incubated with 125μL of spiked 
plasma, at a concentration of 1 femtomole mL-1 IglC aa49-61 peptide and 1280 CFU 
mL-1 bacteria, respectively.  Although this method is not as sensitive for the detection 
of F. tularensis bacteria in blood as it is for the detection of bacteria in PBS solution, 
the detection limit is still comparable to most ELISA methods (43, 51). However, our 
technology has the advantage of greater safety because we are detecting bacterial 
peptides after the bacteria have been inactivated by lysis and proteolysis.  In 
addition, our technology has higher specificity, since tandem mass spectrometry is a 
molecular approach with sequencing capabilities to provide absolute identification of 
the target molecule. 
 
Due to the high virulence of bioterrorism pathogens, high sensitivity is one of 
the most important requirements in order to avoid “false negative” results.  The 
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sensitivity in plasma (800 CFU) is lower than in PBS solution (ca. 10 CFU bacteria), 
may be due to incomplete digestion and to high levels of non-specific binding of 
other plasma proteins which can suppress the ion signal from the target peptide.  
Optimized sample preparation protocols may alleviate this problem.  In particular, a 
major advantage of this MS/MS-based technique is that the proteins which are the 
source of these non-specifically-bound peptides can be identified from the MS/MS 
spectra of their peptides, and depletion protocols can be specifically designed to 
remove these proteins prior to digestion and affinity capture of the target peptides 
(52).  Improved sample preparation protocols, and improvements in mass 
spectrometric detection technology, should lead to routine detection sensitivities of 
~10-100 attomoles of peptide. 
 
3.5.1.3 Detection of F. tularensis bacteria in Nasal swab samples 
The F. tularensis iMALDI assay is also usable for nasal swab analyses. Nasal 
swabs are widely used in clinical tests, and are a simple and useful method for 
collecting a wide range of respiratory viruses.  The collection of a nasal swab is easy 
and painless, and it can easily be performed in remote locations (53).  In the mouse 
nasal swab samples collected 2 days after inoculation, a very low level of target 
peptide (m/z=1344.7) was detected, while in the uninfected mouse samples the 
signal for this peptide was not detected (Figure 5).   No bacteria were observed in a 
culture of the nasal swab solution from the infected animal (which later developed 
tularemia), thus demonstrating that iMALDI could detect F. tularensis at levels too 
low for successful culturing of the bacteria.  
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3.5.2 Specificity 
By “specificity” of the assay, we mean that the target peptide is unique to the 
organism (as determined by a BLAST search of the peptide sequence).  Thus the 
detection of this peptide, at the appropriate MW and with the correct sequence is a 
positive indication of the presence of F. tularensis.  The iMALDI can provide this 
specificity by combining two molecular characteristics of the epitope-containing 
peptides: i) the molecular weight, typically measured by MALDI-MS within an error of 
≤100 ppm and ii) the amino acid sequence, determined by performing MS/MS on the 
same sample.  
 
We have demonstrated that this iMALDI technology is able to accurately 
determine the molecular weight of an immunoaffinity-enriched F. tularensis peptide 
from a proteolytic digest of F. tularensis bacteria in PBS solution and blood.  The 
molecular weight determination was accurate to within 60 ppm.  Sequence 
information on the affinity-bound peptide was also obtained by MALDI-MS/MS 
(Figure 6A).  MS/MS analysis produces high-abundance sequence-specific ions, 
resulting in an almost complete amino acid sequence of the peptide.  These 
sequence-specific ions allow confident assignment of the target peptide (Figure 6B).  
Using the existing NCBInr database (2006.02.16), searching with only MS data, we 
retrieved 74,528 hits out of more than 3 million entries; in contrast, searching with 
combined MS and MS/MS data, resulted in only one hit (Figure 6C).  This 
demonstrates the specificity of this iMALDI technique for detecting F. tularensis.  
Here, we used polyclonal antibodies because of their ready availability.  Polyclonal 
antibodies often contain more than a single epitope within a particular stretch of 
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amino acids, and therefore, are able to capture even modified peptides since they 
are likely to contain an unmodified stretch of amino acids. This makes this detection 
method tolerant of small sequence variations.  On the other hand, the use of 
polyclonal antibodies might lead to cross-reactivity with peptides from other species.  
This could decrease specificity and/or the detection limit of our method.  This issue 
could be resolved by using a several monoclonal antibodies, or perhaps even both 
types of antibodies, for the final clinical version of this technique 
 
3.5.3 Quantitation 
 To determine the absolute concentration of a given peptide in a sample (and, 
therefore, the absolute concentration of the original protein, which should correlate 
with the number of bacteria in the sample), synthetic stable-isotopically labeled 
“heavy” peptide is used as an internal standard.  These heavy peptides are identical 
in amino acid sequence to the native epitope-containing “light” peptides from the 
protein in the sample, but are higher in mass and are thus distinguishable by mass 
spectrometry.  The heavy peptide is added to the proteolytically-digested protein 
sample prior to incubation with the immobilized anti-peptide antibody.  Following 
affinity enrichment of the target peptides, MALDI-MS analysis of the antibody beads 
shows doublets of ion signals from the light and heavy peptides, whose intensity 
ratios can be used for absolute quantitation. 
For quantifying F. tularensis IglC protein, the F. tularensis IglC aa 49-61 
peptide 49NIVAIEGGEDVTK61 was synthesized with an isotopically-labeled valine at 
position 59 (underscored).  This “heavy” peptide (H) is identical in amino acid 
sequence to the native epitope-containing “light” peptide (L), but is 6 Da higher in 
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mass (m/z=1350.7) due to 6 13C’s in place of 6 12C’s.  In these experiments, the 
heavy peptide was added in various amounts (100 fmol – 5 pmol) to a proteolytic 
digestion of F. tularensis bacteria in buffer, and was immuno-adsorbd using the anti-
F. tularensis IglC aa49-61 antibody, immobilized on affinity beads (Figure 7A-D).  
Analysis of an aliquot of these beads spotted directly on the MALDI target reveals 
monoisotopic protonated molecular ions from the two peptides, separated by 6 Da.  
Figure 7E shows a linear correlation (R2=0.9988) between the ratio of the two 
peptides (H/L) and the amount of H spiked in as internal standard over near two 
orders of magnitude (from 100 fmol to 5 pmol). The nearly perfect linear correlation 
demonstrates the accuracy of iMALDI2 for the absolute quantitation of F.tularensis 
peptides/proteins using an internal standard. 
 
3.5.4 Conclusion 
 It has been shown that the combination of two mass spectrometric 
approaches (MALDI-MS and MALDI-MS/MS), inherent in the iMALDI approach, can 
unambiguously identify affinity-bound peptides, and therefore, permits specific 
detection of F. tularensis bacteria.  The F. tularensis iMALDI can detect F. tularensis 
bacteria in environmental samples at a sensitivity of better than 10 CFU of bacteria.  
The high sensitivity of this technique means a low rate of “false negatives”, and the 
high specificity means a low rate of “false positives”, since both the molecular weight 
and the sequence of the bacterial peptide are determined at high accuracy.  In 
addition, the F. tularensis iMALDI assay is adequate for accurate and absolute 
quantitation of the target protein concentration.  With the addition of robotic liquid 
handling systems, it would be an even safer technique, as well as being capable of 
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high-throughput analyses.  This would make iMALDI an extremely valuable tool for 
the early detection of F. tularensis and other bioterrorist agents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
4 DEVELOPMENT AND APPLICATION OF iMALDI FOR EGFR DIAGNOSIS  
 
4.1 EGFR and cancer 
Cancer is a complex disease, caused by uncontrolled, abnormal cellular 
growth through oncogenic and anti-apoptotic pathways with multiple mechanisms.  
One key player of cell growth is the epidermal growth factor receptor (EGFR), a 
member of the ErbB family of membrane-associated receptor tyrosine kinases. 
EGFR, a 170 kDa transmembrane glycoprotein, consists of an extracellular ligand-
binding domain, a membrane-spanning domain, and an intracellular cytoplasmic 
tyrosine kinase domain (54).  In response to a number of ligands, EGFR and its 
ErbB family members can homo- and heterodimerize, eliciting a variety of signaling 
transduction events that can affect cell growth and adhesion, migration, 
differentiation, and apoptosis (55).  EGFR up-regulation is frequently observed in a 
number of cancers, such as prostate, lung, ovary, and breast cancers (56-59) . This 
up-regulation can deregulate multiple signaling pathways, which lead to increased 
proliferation and inhibited apoptosis.  High EGFR level has been related to poor 
response to treatment and decreased survival times (58, 60).   
 
4.2 Currrent techniques 
Immunohistochemistry (IHC) is frequently used to determine EGFR protein 
expression.  However, IHC techniques have limited sensitivity and quantitation 
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capability of EGFR expression (54).  IHC cannot quantitate the expression and 
modification of multiple proteins in a single, high-throughput assay format.  Other 
methods, such as Western blot analysis and enzyme-linked immunosorbent assay 
(ELISA), have limitations the same as IHC, such as limited sensitivity and 
quantitation capability.  Northern blotting or quantitative reverse transcription 
polymerase chain reaction (RT-PCR) assess mRNA levels, but there may be 
problems caused by RNA degradation and contamination.  Furthermore, mRNA 
levels cannot predict post-translational modifications and do not always correlate 
with actual cellular protein levels or activity (61, 62). 
New proteomics technologies, such as surface-enhanced laser 
desorption/ionization MS (SELDI), are used to identify potential cancer biomarkers 
(61-65).  In SELDI, bait proteins, such as antibodies, are immobilized on chemically 
modified surfaces to capture intact analyte proteins for MS analysis.  However, 
proteins, extremely sensitive to surface substrate physico-chemical properties, are 
easily denatured.   MS analysis of full-length proteins suffers from limited resolution, 
preventing identification based solely on mass.  When detecting proteins in complex 
biological samples is attempted, the heterogeneity, hydrophobicity, and limited 
solubility of proteins may introduce significant loss-associated bias. 
 
4.3 iMALDI for EGFR 
The iMALDI assay for detecting EGFR is based on affinity capture of the 
tryptic peptide aa 963-975 from EGFR.  This assay circumvents many problems 
described above, and is able to detect EGFR in mammalian breast cancer cell lines 
and tumors sensitively, specifically, and quantitatively., 
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4.4 Materials and methods 
4.4.1 EGFR 
EGFR protein (human) was purchased from SIGMA (Saint Louis, MI).   
 
4.4.2 Breast cancer cell lines and tumor lysates 
ME16C, SUM102 
(http://www.asterand.com/Asterand/BIOREPOSITORY/102PT.aspx), and MCF-7 cell 
lines, and the BR97-0137B tumor sample, were obtained from the Perou lab (LCCC, 
UNC-CH) as cell lysates, extracted from a fresh frozen tumor sample of BR97-
0137B and cell lines using Pierce’s Tissue (T-PER) and cell line (M-PER) protein 
lysate extraction kit (Pierce).  The protein concentration of the whole cell lysate was 
determined using Pierce’s Micro BCA assay according to the manufacturer’s 
protocol. 
 
4.4.3 Tryptic digestion 
Digestion was carried out in 25mM ammonium bicarbonate (Sigma) at 37oC 
overnight, with an enzyme:substrate ratio of trypsin (Sequencing-grade modified, 
Promega) to protein of around 1:10.   
 
4.4.4 Antibody Production and Immobilization of antibodies on beads 
One of the tryptic peptides from EGFR with high sensitivity in the MALDI-MS 
mode (Figure 8) was seleced as the target, against which an antibody was raised.  
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This antibody was then covalently immobilized on CNBr-activated Sepharose beads 
(Amersham Pharmacia) according to the manufacturer’s instructions (48).   
 
4.4.5 Immuno precipitation Protocol 
Affinity binding was carried out in compact reaction columns (CRC) (USB). An 
aliquot of antibody beads (1-5 uL) was loaded into a CRC, and then washed 4-6 
times with 400 μL of 0.1x PBS.  The synthetic peptide, C963MHLPSPTDSNFYR975 
(Biosynthesis) with an additional N-terminal cysteine residue which was added for 
ready conjugation with carrier proteins,.was dissolved in HPLC water, and then 
diluted to a series of concentrations, e.g. 150 ng/μL, 15 ng/μL, 1.5 ng/μL, etc.  A 10 
μL of each solution was incubated with an aliquot (1~5 μL) of antibody-beads to 
immuno-adsorb the epitope-containing peptide.  Immuno-adsorption of tryptic 
digests of the EGFR protein, cell lysates or tumor biopsy samples was carried out 
similarly.  Incubation of PBS and conjugated or unconjugated agarose beads were 
used as negative controls.  
 The beads were incubated for 2-4 h at room temperature with end-to-end 
rotation on a “Labquake” shaker (Lab Industries), and then washed 6 times with 400 
μL of freshly-made 50 mM ammonium bicarbonate, or 3 times with 400mM of NaCl 
(Sigma) followed by 3 times with 50 mM ammonium bicarbonate in cases where 
high levels of non-specific binding was expected.  After resuspended in a small 
volume of 50 mM ammonium bicarbonate (1-5 μL), an aliquot of the beads (0.5 μL) 
was spotted directly onto the MALDI target for analysis. 
 
4.4.6 Isotopic Labeling for absolute Quantitation 
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The heavy EGFR aa 963-975 peptide (963MHLPSPTDSNFYR975) containing 
an isotopically-labeled leucine at position 965 (underscored) was synthesized with a 
2H-labeled FMOC leucine purchased from C/D/N ISOTOPES (Quebec, Canada) at 
the UNC peptide synthesis facility (49).  The increase in mass was 10 Da from the 
unlabeled EGFR aa 963-975 peptide. 
 
4.4.7 Absolute Quantitation 
The heavy peptide, used as an internal standard, was accurately weighed on 
a microbalance and dissolved in water (HPLC grade, Pierce).  Various amounts of 
the heavy peptide was spiked into the tryptic digest of SUM102 cell lysate, incubated 
with anti-EGFR peptide antibody beads, and quantitated by MALDI-MS analysis of 
the beads deposited directly on the MALDI target. 
 
4.4.8 Mass Spectrometric Analysis 
All MALDI-MS and MS/MS experiments were carried out on a MALDI-TOF 
instrument (Ultraflex) from Bruker Daltonics (Billerica, MA) with their Anchor-chip™ 
MALDI-target plates (400 or 600 μm/384 spot format).  α-cyano-4-hydroxycinnamic 
acid (HCCA) (Sigma) re-crystallized from hot methanol was used as matrix for all 
experiments.  The solvent for HCCA was a mixture of 50% acetonitrile (Caledon 
Laboratories), 49.9% water (HPLC grade, Pierce), and 0.1% trifluoroacetic acid 
(Pierce) (v/v/v).   
After the antibody beads were placed on the target, 0.5 μL of a saturated 
solution of HCCA matrix was added, and the spot was air-dried at room temperature. 
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4.5 Results and Discussion 
4.5.1 Sensitivity Studies – synthetic peptide    
The iMALDI technology was able to detect the synthetic EGFR peptide as low 
as one attomole in buffer.  In contrast, without enrichment by iMALDI, MALDI-MS 
analysis of the peptide solution could only detect the peptide in the low femtomole 
range in buffer (5 femtomole) (Figure 9).  This decreasing in detection sensitivity is 
likely due to the peptide absorption by the walls of the tubes and by the pipette tips 
during the sample preparation process.  While using the enrichment procedure, the 
peptides are bound to the antibody beads, greatly reducing the absorption and 
therefore the peptide loss.  
The S/N ratio of the signal from the 1 attomole with iMALDI (Figure 9B) is 
higher than that of the 10 femtomole and 100 attomole levels, because the co-
crystallization is not uniform, and for the 1 attomole level, apparently a better crystal 
was sampled than for the 10 femtomole and 100 attomole levels.  
 
4.5.2 Breast Cancer Cell Lines   
Both EGFR-expressing mammalian breast cancer cell lines, SUM102 is a 
tumor-derived basal-like cell line (66), and ME16C is a mammary epithelial cell line 
immortalized with hTERT with characteristics of the basal-like subtype(66).  
 
4.5.2.1 SUM102 Cell Lysate   
EGFR was detected in a SUM102 cell lysate equivalent to 10 cells.   The cell 
lysate digest was incubated with a small aliquot (1-5 μL) of anti-aa963-975 EGFR 
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antibody beads, one tenth of which were spotted directly on the MALDI target plate 
and analyzed.  The epitope-containing target peptide (aa 963-975 
MHLPSPTDSNFYR) with an m/z of 1564.7 was observed (Figure 10).   
EGFR was also quantitated in SUM102 absolutely.  Unlike in “relative 
quantitation,” where the ratios of the peptide concentrations in two samples are 
compared,  in “absolute quantitation,” the absolute amount of the peptide was 
determined.  Before incubation with the immobilized anti-peptide antibody, the 
synthetic stable-isotopically labeled peptide (heavy peptide), is added to the 
proteolytically-digested protein sampleas internal standard.  MALDI-MS analysis of 
the antibody beads after immuno-adsorption shows doublets of ion signals from the 
light and heavy peptides, whose intensity ratios are used for absolute quantitation. 
The heavy peptide (H) EGFR aa 963-975 peptide 963MHLPSPTDSNFYR975, is 
identical in amino acid sequence to the native epitope-containing peptide (light 
peptide, L, m/z=1564.7), but is 10 Da higher in mass (m/z=1574.7).  The heavy aa 
963-975 peptide (H) was added in various amounts to the tryptic digest of SUM102 
cell lysate, and immuno-adsorbd using the immobilized anti-EGFR aa 963-975 
antibody (Figure 11A-B).   
Analysis of an aliquot of the beads (ca. 10%) shows that the monoisotopic ion 
signals of the two peptides can be distinguished from each other by a mass 
difference of 10 Da.  The logarithmic plot (Figure 11C) shows a linear correlation 
(slope is approximately one) between the signal intensity ratio of the two peptides 
(H/L) and the amount of the internal standard (H) over near two orders of magnitude,  
demonstrating the accuracy of this assay for the absolute quantitation of EGFR 
peptides by using an internal standard.  
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With this standard curve, the amount of EGFR in SUM102 cells was 
determined. The amount of EGFR peptide is equal to the amount of digested EGFR 
protein in the cell lysate, which is equal to the amount in the original cell lysate and 
cells, assuming 100% efficiency of the digestion reaction and the protein extraction 
upon cell lysis.  The concentration of EGFR was determined to be 0.65 
attomoles/cell, or approximately 390,000 EGFR molecules per SUM102 cell, Which 
is consistent with the EGFR number (~50,000) in HeLa cell in the literature(67).   
 
4.5.2.2 ME16C Cell Lysate   
The iMALDI assay was also able to detect EGFR aa963-975 peptide in the 
ME16C cell lysate (Data not shown).    
 
4.5.2.3 MCF-7 Cell Line 
The assay was repeated for the MCF-7 cell lysate, which is a tumor-derived 
luminal cell line that does not express EGFR.   The target peptide was not detected 
(Data not shown). 
 
4.5.3 Human Breast Cancer Tumor Biopsy Sample   
 An estrogen receptor negative and HER2-negative breast tumor biopsy 
sample, BR97-0137B, was analyzed.  BR97-0137B had been previously shown to 
be a grade III infiltrating ductal carcinoma that has gene expression characteristics 
of the basal-like subtype and high gene expression of EGFR (68).    
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 Ion signals of the target peptide (m/z=1564.7) was detected from the digest 
of BR97-0137B tumor tissue lysate with an S/N>5. (Figure 12)   It is important to 
note that less than 1/25 of the biopsy sample was consumed.  
 
4.5.4 Specificity 
The molecular weight of the EGFR peptide was determined to be within an 
error of 75 ppm or better.  In addition, sequence information of the affinity-bound 
EGFR aa963-975 peptide from the ME16C cell lysate digest was obtained by 
MALDI-MS/MS (Figure 13).  Tandem MS analysis provides sequence-specific ions, 
such as the highly abundant y1, y5 and y12, and several lower abundant ones.  The 
mass accuracies of these sequence-specific ions are similar to that obtained in the 
MS mode, allowing confident assignment.   The absences of y7 and y9, produced by 
C-terminal fragmentation of Pro, increases confidence in the assignment.  In the 
existing NCBI database, searching with MS data only, 33,129 hits were obtained out 
of 2 million entries, which means about 33,129 out of 2 million peptides have 
masses around 1344.7.  While searching with both MS and MS/MS data, one hit 
was obtained.  This data clearly demonstrates that the combination of the two mass 
spectrometric approaches (MALDI-MS and MALDI-MS/MS) inherent in the iMALDI 
assay, is capable of unambiguously identifying affinity-bound peptides, permitting 
highly specific detection of EGFR. 
 
Based on affinity capture by the antibody, this technique may induce false 
negatives due to target sequence variation.  If a key amino acid residue in the 
epitope-containing region of the peptide is substituted, the antibody may fail to 
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capture the peptide, resulting in a “false negative.”   To eliminate this problem, other 
antibodies can be used at the same time in the assay to target multiple epitopes, 
providing more coverage of the protein.  Moreover, polyclonal antibodies are used in 
this assay.  Because more than a single epitope may be contained within a particular 
stretch of amino acids, modified peptides are likely to contain enough unmodified 
parts to be captured by the polyclonal antibodies.  Mutations in the DNA could lead 
to unexpected amino acids in the target peptide sequences, which would be 
detected by the MS/MS sequencing of the captured peptides, revealing the 
homology.  In addition, current database searching programs, such as the 
MASCOTTM software, can identify peptides with substitutions and/or deletions.  All 
these will reduce “false negatives”. 
 
4.6 Concluding remarks 
The iMALDI assay for EGFR using the anti-EGFR aa 963-975 antibody, 
detected EGFR in mammalian breast cancer cell lines ME16C and SUM102 where it 
is known present, and not in the MCF-7 cell line where it is known NOT present.  It 
also detected EGFR in a human breast tumor biopsy sample.  This iMALDI has 
achieved sensitivities in the low attomole range, high specificity, and absolute 
quantitation of target peptides with a linear dynamic range of over two orders of 
magnitude.  The sensitivity of the EGFR iMALDI assay allows the detection of EGFR 
from the cell lysate corresponding to a few (≦10) SUM102 cells, and the specificity 
of the assay ensures a low rate of false positives. 
 
 
CHAPTER 5 
5 FUTURE DIRECTIONS 
 
5.1 Protocol optimization 
The protocols for samples preparation can be further optimized in order to 
achieve higher sensitivity and decreased assay times.  
 
5.1.1 Pre-depletion of plasma 
Sensitivity is one of the most critical parameters affecting the utility of the 
iMALDI assay, especially for diagnosis of infectious pathogens such as F. tularensis.  
Insufficient sensitivity to detect the pathogens at trace levels can lead to “false 
negative” results.  Although this iMALDI assay can detect as few as ten CFU F. 
tularensis bacteria in buffer (environmental samples), its sensitivity of bacteria in 
plasma (800CFU) might not be enough for clinical diagnosis.  This may be due to 
the complexity of plasma.  Other more abundant peptides from the tryptic-digested 
plasma may compete with the low level of target peptide during the immunoaffinity 
capture by the antibody beads. The high level of non-specific binding of other 
peptides greatly suppresses the ion signal from the target peptide.  This problem can 
be eliminated through optimizing the protocols for sample preparation. In particular, 
the proteins which are the source of these non-specifically-bound peptides will be 
identified from their MS/MS spectra, and these proteins will be depleted from the 
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plasma using commercially-available or customized depletion kits prior to affinity 
capture of the target peptides.  
 
5.1.2 Digestion  
Currently the digestion is carried out at 37oC overnight.  The use of long 
incubation times and elevated temperatures inevitably leads to more digestion 
artifacts like nonspecific cleavage, which will lead to failure of affinity capture of the 
targets by the antibody beads, giving rise to “false negatives”. By using immobilized 
trypsin, digestion can be done at the room temperature.  Because the effective 
protease concentration on the solid support is very high, digestion efficiency can be 
strongly enhanced and digestion times will be greatly reduced.  
The digestion efficiency of proteins can also be enhanced by the use of 
organic solvents during digestion. This is because proteins tend to denature in the 
presence of organic solvents such as acetonitrile, thereby increasing cleavage-site 
accessibility.  
 
5.1.3 Use of nanoparticles 
Antibody beads can be made by nanoparticles.  Compared to the micro 
affinity beads that are used now, the nanoparticle has a larger surface area-to-
volume ratio.  The higher density of antibodies on the surface of the nanoparticles, 
will lead to improved rate constants for the association of analytes with the antibody-
conjugated nanoparticles, and therefore improved sensitivity, and reduced 
incubation time. 
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5.1.4 Smaller spot 
After the incubation for affinity capture, using the robotic spotting machine, 
the antibody beads can be deposited onto smaller spots on the target, like 400um 
and 200um (currently 600um).  This is expected to increase the surface 
concentration of the analytes, which will also improve the sensitivity. 
 
5.1.5 More sensitive mass spectrometer 
Technology is still developing.  There will be more sensitive mass 
spectrometers. Our collaborator, Bruker Daltonics, will develop specialized mass 
spectrometers for analysis of beads. 
 
5.2 Multiple targets 
With any antibody-based technique there is the possibility of false negatives 
due to strain variation or gene mutation.  If there has been a substitution of a key 
amino acid residue in the epitope-containing region, the protein or peptide may not 
be captured by the antibody, resulting in a “false negative”.  To eliminate this 
problem, multiple target proteins can be selected. For each target protein, several 
peptides can be selected as the targets. This would provide more coverage of each 
targeted protein.  Polyclonal antibodies against 12-17 amino acid peptides can be 
used instead of monoclonal antibodies, and more than a single epitope will be 
contained within this stretch of amino acids.  Therefore, even modified peptides are 
likely to contain enough of an unmodified stretch to be captured by these polyclonal 
antibodies.  Moreover, it is highly unlikely that all target peptides would be mutated, 
so several characteristic peptides should still be detected by this assay.  Mutations 
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in the DNA could lead to failure of the PCR-based assays and unexpected amino 
acids in the target peptide sequences.  But these would be detected by the MS/MS 
sequencing of the captured peptides. In addition, current database searching 
programs, such as the MASCOT software, can identify peptides with substitutions 
and/or deletions.  If determination of bacterial strains proves to be of clinical interest, 
the iMALDI is an extremely flexible format, and beads containing antibodies raised 
against peptides which are characteristic of the different strains could simply be 
added to the chip. 
 
5.3 Automation& high throughput 
The enrichment capability of using immobilized antibodies allows the 
detection of bacteria at low concentrations by using more sample and by using fewer 
beads, thereby increasing the number of bound peptides per bead.  However, it 
becomes very difficult to handle a low amount of beads manually, but this limitation 
can be circumvented by using automated robotic systems.  Automation is essential 
for bioweapons diagnosis because of the danger inherent in handling these 
organisms, and is also an essential component of high-throughput analysis.  
Biomachines, one of our collaborators, is developing the state-of-the-art robotic 
systems, based on the MALDI spotting machine, to adapt this iMALDI technology for 
automated high throughput analysis. It will provide a routine detection sensitivity of 
~10-100 attomoles of peptides and increased sample throughput. It will be able to 
operate in a safe environment, which will reduce both the possibility of the operator’s 
exposure to the pathogen, and the possibility of contamination of the samples. 
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The proof-of-principle study has demonstrated the possibility to integrate and 
fully automate the iMALDI protocols using a robot designed for a different intended 
use.  A smaller clinical quality processor will be designed and built specifically for 
iMALDI.   
The key components of the iMALDI Processor will be a vision-guided small-
volume liquid handling robot, including a multi-purpose station for incubating, mixing, 
and washing, disposable reaction vessels, a MALDI spotting station, and a storage 
station for chilling and resuspending reagents.   All parts will be enclosed and 
equipped with HEPA (high-efficiency paniculate air) filtered airflow to ensure sterility.  
The vision system will be used for interactive teaching during set-up to guide 
precision deposition of the beads, and for post process inspection and clinically 
required quality control. The disposable reaction vessel can be a single chamber; or 
for high volume processing, a multiwell filter plate, from a 96-well filter plate to a 384-
well filter plate, depending on the required throughput; or for low volume work, 
similar to unitized micro chromatography columns, held in a rack placed in the same 
multi-purpose chamber as the filter plate.  Samples, trypsin and beads are stored in 
a chiller which also keeps the beads in suspension by mixing.  All surfaces will be 
easily accessible and made of inert materials such as stainless steel so that they 
can be aggressively cleaned to inactivate and remove contaminating materials.  
The disposable reaction vessel(s) are loaded into a central multi-purpose 
station for incubating, mixing, and washing:  1) pathogens such as bacteria are 
inactivated by ethanol followed by boiling; 2) the whole proteome is proteolytically 
digested at 37oC with gentle mixing; 3) beads with immobilized antibodies are added 
and incubated with the digested sample at room temperature; 4) unbound materials 
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are removed by washing.  In Step 5, resuspended beads are deposited onto a 
MALDI target with matrix and then analyzed.  For complete automated diagnosis, 
the only manual part will be introducing the sample to the robotic system and 
inserting the MALDI target into the mass spectrometer, like a “push button”. Thus, 
the operation does not require any specific knowledge or skills in microbiology, 
protein chemistry, mass spectrometry, or computational sciences, and can be 
operated by low-level technicians. 
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Figure 1: Analytical scheme of the iMALDI assay.  
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Figure 2:  Selection of F. tularensis IglC peptides for raising antibodies to be 
used for the Francisella tularensis iMALDI assay.  A) MALDI-MS of proteolytic F. 
tularensis IglC peptides obtained by in-solution digestion of IglC with trypsin.  Four 
“true” (C-terminal cleavage of K or R residues) tryptic peptides of IglC (shown in blue) 
were selected for antibody production based on the high sensitivity in the MALDI-MS.  
B) Affinity determination of the four anti-(F. tularensis IglC) peptide antibodies 
against their epitope peptide by ELISA.  The cysteine residue marked with asterisk 
has been added to the native sequence because of ease of conjugation with the 
carrier protein. 
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 Figure 3: Detection sensitivity of synthetic F. tularensis IglC peptides in 
solution and using the F. tularensis iMALDI assay.  A) MALDI-MS spectrum of 
synthetic F. tularensis IglC peptides CNIVAIEGGEDVTK in solution:  A-1) 100 
femtomole; A-2) 10 femtomole; A-3) 1 femtomole; A-4) 100 attomole; A-5) 10 
attomole.  B) MALDI-MS spectrum of synthetic F. tularensis IglC peptides 
CNIVAIEGGEDVTK affinity-bound to anti-aa48-61(F. tularensisp23) antibody beads: 
B-1) 138 femtomole; B-2) 13.8 femtomole; B-3) 1.38 femtomole; B-4) 138 attomole; 
B-4) 13.8 attomole. 
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 Figure 4:  Detection of F. tularensis bacteria in environmental samples using 
the F. tularensis iMALDI assay.  MALDI-MS spectrum of peptides obtained after 
proteolysis of F. tularensis bacteria in buffer, affinity-bound to anti-aa49-61 (F. 
tularensis IglC) antibody beads. The singly-charged epitope-containing tryptic 
peptide (aa 49-61 F. tularensis IglC protein) is observed at m/z = 1344.7 (see inset).  
The spectrum represents the amount of IglC peptide equivalent to 8 CFU for F. 
tularensis bacteria. 
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Figure 5:  Detection of F. tularensis bacteria in nasal swab samples using the F. 
tularensis iMALDI assay.   A) MALDI-MS spectrum of peptides affinity-bound to 
anti-aa49-61 (F. tularensis IglC) antibody beads, obtained after proteolysis of mouse 
nasal swab extracts collected two days after the mice were inoculated with F. 
tularensis  The singly-charged, epitope-containing, tryptic peptide, 
NIVAIEGGEDVTK, corresponding to aa 49-61 of the F. tularensis IglC protein, was 
observed at m/z = 1344.7 (see inset).  B) MALDI-MS spectrum of anti-aa 49-61 (F. 
tularensis IglC) antibody beads obtained after proteolysis of nasal swab extracts 
collected from uninfected mice on the same day.   
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Figure 6:  Highly specific detection of F. tularensis bacteria in environmental 
samples by mass spectrometric sequencing of the immunoaffinity-enriched F. 
tularensis IglC aa49-61 peptide, using the F. tularensis iMALDI assay.  A) 
MALDI-MS/MS spectrum of the peptide at m/z = 1344.7 affinity-bound to anti-[aa49-
61(F. tularensis IglC)] antibody beads, obtained after proteolysis of F. tularensis 
bacteria in buffer.  All of the abundant ions can be assigned to sequence-specific y- 
and b-ions of the F. tularensis IglC peptide aa49-61, resulting in unambiguous 
identification of the immunoaffinity-enriched peptide.  B) This table shows the mass 
accuracies of the fragment ions, demonstrating that the assignment of these ion 
signals is correct.  This therefore demonstrates that, using our F. tularensis peptide 
chip, F. tularensis bacteria can be detected with high specificity and correspondingly 
low false positive rates.   C) Database search results for the peptide 
NIVAIEGGEDVTK in the NCBI database with MALDI-MS and MALDI-MS/MS data. 
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 Figure 7:  Quantitation of F. tularensis bacteria using the F. tularensis iMALDI 
assay.  Absolute quantitation of the IglC peptide NIVAIEGGEDVTK (aa 48-61) (L, 
light peptide, m/z = 1344.7) in a bacterial sample.  F. tularensis bacteria were 
digested and incubated with different amounts of heavy peptides (H, m/z =1350.7) 
as internal standards: A) 0.1 pmol, B) 0.5 pmol, C) 1 pmol, D) 5 pmol, E) Plot of the 
observed ratios of monoisotopic abundances of H and L in the MALDI-MS spectra 
(A-D) versus the absolute amount of H added.  Note, only a 10% aliquot has been 
used for the analysis. 
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 Figure 8:    Selection of EGFR peptides to be used for raising antibodies for 
the EGFR iMALDI assay.   MALDI-MS of proteolytic EGFR peptides, obtained by in-
solution digestion of EGFR with trypsin.  The “true” (C-terminal cleavage of K or R 
residues) tryptic peptide of EGFR of m/z 1564.7 (sequence shown in inset) was 
selected for antibody production based on its high sensitivity in the MALDI-MS mode.   
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 Figure 9:   Comparative study to determine the sensitivity of MALDI-MS 
analysis of the EGFR peptide aa 963-975 A) from solution and B) using our 
iMALDI technology.  The EGFR peptide aa963-975 of m/z = 1667.7 was used for 
raising antibodies, and is identical to the native EGFR peptide aa963-975, with the 
addition of an N-terminal cysteine residue (C963MHLPSPTDSNFYR975) to facilitate 
conjugation with carrier proteins. 
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 Figure 10:  Detection of EGFR using the EGFR iMALDI assay in mammalian 
breast cancer cells.  MALDI-MS spectrum of peptides affinity-bound to anti-aa963-
975 EGFR antibody beads obtained after lysis of SUM102 cells, followed by 
proteolysis with trypsin.  The singly-charged, epitope-containing, tryptic peptide aa 
963-975 MHLPSPTDSNFYR of the EGFR protein is observed at m/z = 1564.7 (see 
inset).  The spectrum represents the amount of EGFR peptide on MALDI target 
equivalent to one SUM102 cell. 
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Figure 11:  Quantitation of EGFR in SUM102 cells using the EGFR iMALDI.  
Absolute quantitation of the EGFR peptide MHLPSPTDSNFYR (aa 963-975) (L, light 
peptide, m/z = 1564.7) in SUM102 cells.  Cells were lysed, digested, and incubated 
with known amounts of heavy peptides (H, m/z =1574.7) as internal standards: A) 
0.1pmol, B) 1 pmol of H.  C) Logarithmic plot of the observed ratios of monoisotopic 
ion abundances of H and L in the MALDI-MS spectra versus the absolute amount of 
H added.   
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 Figure 12:  Detection of EGFR using the EGFR iMALDI assay in the basal-like 
primary human tumor BR97-0137B.  MALDI-MS spectrum of peptides affinity-
bound to anti-aa963-975 EGFR antibody beads obtained after lysis of BR97-0137B 
cells, followed by tryptic proteolysis.  The singly-charged, epitope-containing, tryptic 
peptide aa 963-975 MHLPSPTDSNFYR of the EGFR protein can be observed at 
m/z = 1564.7 (see inset).   
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Fragment ions m/z observed m/z theoretical Mass accuracy (ppm) 
y1 174.884 175.120 -1348 
b2 268.785 269.107 -1197 
y2 337.799 338.183 -1135 
b3 381.839 382.191 -921 
y4 598.908 599.294 -644 
y5 685.887 686.326 -640 
y8 998.796 999.454 -658 
y12 1433.062 1433.681 -432 
 
Figure 13:  Highly-specific detection of EGFR in ME16C cells by mass 
spectrometric sequencing of the immunoaffinity enriched EGFR aa963-975 
peptide using the EGFR iMALDI.  The sequence-specific b and y-ions of the 
peptide at m/z = 1564.7 affinity-bound to anti-aa963-975 EGFR antibody beads 
observed in MALDI-MS/MS spectrum after lysis and proteolysis of ME16C cells. 
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